Over the last decade, pioneering molecular gene therapy for inner-ear disorders have
achieved experimental hearing improvements after a single local or systemic injection of …

Adeno-associated viruses (AAVs) are viral vectors that offer an excellent platform for gene
therapy due to their safety profile, persistent gene expression in non-dividing cells, target …

Cochlear gene therapy can be a new avenue for the treatment of severe hearing loss by
inducing regeneration or phenotypic rescue. One necessary step to establish this therapy is …

Approximately 3 in 1000 children in the US under 4 years of age are affected by hearing
loss. Currently, cochlear implants represent the only line of treatment for patients with severe …

Hearing impairment is the most common sensory disorder in humans. So far, rehabilitation
of profoundly deaf subjects relies on direct stimulation of the auditory nerve through cochlear …

Adeno-associated virus (AAV) has been successfully used to deliver gene therapy to
improve auditory function in mouse models of hereditary hearing loss. Many forms of …

The mouse serves as a valuable model for treatment leading to the prevention and therapy
of inner ear disease. Transgenic correction of genetic inner ear disease in mice may help …

Balance dysfunction is closely associated with loss of vestibular hair cells (HCs). Gene
therapy shows promise when used to protect or regenerate vestibular HCs to preserve or …

Objective: To investigate the expression of the miniature pig cochlea after AAV1 transfect
into the cochlea via round window membrane (RWM). Methods: Twenty miniature pigs are …

The survival of the auditory nerve in cases of sensorineural hearing loss is believed to be a
major factor in effective cochlear implant function. The current study assesses two measures …